Skip to main content

Table 3 Descriptive statistics and results of the regression models

From: Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study

Variable

International model

German model

Description

OR (95% CI)

Description

OR (95% CI)

Patient characteristic

 Age, mean ± SD, years

66.9 ± 9.9

 

68.7 ± 9.1

0.86 (0.78–0.96)

 Sex, n (%)

  Male

1444 (59.2)

1.36 (1.03–1.8)

107 (60.5)

 

  Female

994 (40.8)

Reference

70 (39.5)

 

 Time since PD diagnosis, mean ± SD, years

7.7 ± 5.9

1.12 (1.08–1.16)

8.0 ± 6.2

1.34 (1.11–1.63)

 UPDRS V: Modified Hoehn & Yahr Staging, mean ± SD

2.5 ± 0.8

2.04 (1.57–2.65)

2.7 ± 0.9

5.74 (1.34–24.58)

Treatment

 Number of current oral treatments, mean ± SD

2.0 ± 1.1

1.19 (1.03–1.37)

2.1 ± 1.0

0.46 (0.18–1.18)

 Delphi 7. ≥ 5 times daily oral levodopa dosing

  Yes

740 (30.5)

2.02 (1.47–2.79)

75 (42.6)

 

  No

1687 (69.5)

Reference

101 (57.4)

 

 Current device-aided treatment (ongoing/about to start), n (%)

  Yes

549 (22.6)

8.68 (5.45–13.82)

31 (17.6)

 

  No

1883 (77.4)

Reference

145 (82.4)

 

Dyskinesia

 UPDRS IV Q32: Dyskinesia (duration), n (%)

  0–25% of day

2074 (85.4)

Reference

152 (85.9)

 

  26–100% of day

355 (14.6)

1.44 (0.95–2.19)

25 (14.1)

 

 Delphi 4. ≥ 2 h of the day with troublesome dyskinesia

  Yes

406 (17)

1.60 (1.02–2.49)

26 (15.4)

 

  No

1985 (83)

Reference

143 (84.6)

 

Motor symptom

 Motor fluctuations, n (%)

  Yes

1352 (55.5)

3.79 (2.78–5.17)

110 (62.1)

49.72 (8.47–291.91)

  No

1086 (44.5)

Reference

67 (37.9)

Reference

 UPDRS III: Motor examination, mean ± SD

25.7 ± 13.9

 

25.6 ± 12.1

1.09 (0.99–1.20)

 Delphi 6. “off” time ≥ every 3 h

  Yes

546 (22.4)

1.56 (1.05–2.33)

40 (22.6)

 

  No

1888 (77.6)

Reference

137 (77.4)

 

Daily living

 Patient requires help at home with daily activities

  Yes

1146 (47.3)

1.78 (1.30–2.43)

99 (56.3)

 

  No/not applicable

1275 (52.7)

Reference

77 (43.8)

 

 Patient lives at a nursing home/other

  Yes

56 (2.3)

4.64 (1.70–12.69)

5 (2.8)

 

  No

2379 (97.7)

Reference

172 (97.2)

 

 UPDRS II: Activities of daily living, mean ± SD

12.5 ± 8.2

1.04 (1.00–1.07)

13.9 ± 6.7

 

 Delphi 8. Moderate or severe limitation of activities of daily living

  Yes

854 (35.5)

1.38 (0.97–1.96)

70 (39.8)

 

  No

1550 (64.5)

Reference

106 (60.2)

 

Health-related quality of life

 PDQ-8 score, mean ± SD

28.9 ± 19.8

1.01 (1.00–1.02)

28.4 ± 17.4

 

Non-motor symptom

 NMSS score, mean ± SD

46.4 ± 39.1

1.00 (0.99–1.00)

52.6 ± 44.2

 

 Delphi 11. Moderate or severe psychosis

  Yes

100 (4.2)

2.61 (1.16–5.88)

7 (4.3)

 

  No

2290 (95.8)

Reference

154 (95.7)

 

 Delphi 5. Non-motor symptoms fluctuations

  Yes

938 (38.6)

 

80 (45.2)

4.31 (1.06–17.54)

  No

1492 (61.4)

 

97 (54.8)

Reference

Physician characteristic

 Unit part of a dedicated referral network for PD, n (%)

  Yes

1714 (70.3)

1.40 (1.04–1.89)

127 (71.8)

 

   No

724 (29.7)

Reference

50 (28.2)

 

 Field of specialty, n (%)

  Neurologist (general)

448 (18.5)

Reference

41 (23.2)

Reference

  Neurologist (movement disorder specialist

1636 (67.5)

0.43 (0.29–0.61)

60 (33.9)

0.19 (0.03–1.16)

  Geriatrician

20 (0.8)

0.20 (0.02–2.78)

0 (0.0)

 

  Other

22 (0.9)

0.45 (0.09–2.32)

0 (0.0)

 

  Multiple

299 (12.3)

0.36 (0.21–0.61)

76 (42.9)

2.62 (0.44–15.45)

Site characteristic

 Site treatment algorithm, n (%)

  Yes

405 (16.8)

2.83 (1.94–4.12)

8 (4.5)

 

  No

2007 (83.2)

Reference

169 (95.5)

 
  1. CI, confidence interval; NMSS, Non-Motor Symptoms Scale for Parkinson’s Disease; OR, odds ratio; PD, Parkinson’s disease; PDQ-8, 8-item Parkinson’s Disease Questionnaire; SD, standard deviation; UPDRS, Unified Parkinson’s Disease Rating Scale
  2. Only variables included in the international or German regression models are shown. Cells highlighted in gray refer to variables, which were not included in the regression model